Analysis and data insight

Despite sluggish fourth quarter, mega-mergers and high-value deals put 2019 at the top

January 14, 2020

Whether the dealmaking momentum of 2019 will continue into 2020 is at the mercy of several uncertainties, not the least of which is the outcome of a U.S. presidential election and continued debates over drug pricing and other legislative issues affecting the industry.

Week in review for Jan. 6-10, 2020: Dealmaking in high gear

January 13, 2020

No Comments

A quick look back at top stories.

Biggest gainers and losers for the week of Jan. 6-10, 2020

January 10, 2020

No Comments

The top 10 biopharma stock gainers and losers for the week.

Money raised by biopharma: 2020 vs. 2019

January 10, 2020

No Comments

Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.

Biopharma money raised: Jan. 1-9, 2020

January 10, 2020

No Comments

Year-to-date money raised in public, private and other financings of biopharma companies.

Phase I clinical trials: December 2019

January 10, 2020

No Comments

Therapeutic area data reported by biopharma companies on phase I trials in December 2019.

Phase II clinical trials: December 2019

January 10, 2020

No Comments

Therapeutic area data reported by biopharma companies on phase II trials in December 2019.

Phase III clinical trials: December 2019

January 10, 2020

No Comments

Therapeutic area data reported by biopharma companies on phase III trials in December 2019.

Notes offerings place 2019 financings at a three-year high, as volumes steadily increase

January 10, 2020

By Karen Carey

No Comments

Med-tech companies brought in more money than each of the last two years in every type of financing, aside from private placements, with about 11% of the funds flowing into digital health companies. In total, the industry raised $40.67 billion, an increase of 98% over 2018, which logged $20.6 billion and was more in line with the $19.4 billion raised in 2017.

M&As will drive momentum

Sector ends year on a high note and positive trend expected to continue

January 10, 2020

By Peter Winter

No Comments

Delegates convening in San Francisco Monday for the 38th Annual J.P. Morgan Healthcare Conference and other related biotechnology conferences running at the same time will certainly be in a better frame of mind than just 12 months ago. Back then, the sector had just come off a terrible fourth quarter, with investors shying away from biopharma company equities big time.